

JFW/1657



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/553,014	Zheng Xin Dong	131P/PCT2/US

INTERNATIONAL APPLICATION NO.
PCT/US04/10891

I.A. FILING DATE	PRIORITY DATE
04/08/2004	04/11/2003

Brian R. Morrill  
Biomeasure, Inc  
27 Maple Street  
Milford, MA 01757-3650



CONFIRMATION NO. 1314

371 FORMALITIES LETTER



\*OC000000019471212\*

Date Mailed: 07/05/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

CC: YANKWICH REF. NO.:  
BIO 131.1 US ✓

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/553,014	PCT/US04/10891	131P/PCT2/US

FORM PCT/DO/EO/922 (371 Formalities Notice)



S/N 10/553,014

Docket: 131P/PCT2/US  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DONG, Zheng Xin et al.

Examiner: Unknown

Serial No.: 10/553,014

Group Art Unit: Unknown

I.A. Filing Date: April 8, 2004

Title: SOMATOSTATIN -DOPAMINE CHIMERIC ANALOGS & USES THEREOF

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV921126788 US with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

July 12 2006  
Date of Deposit

Dawn M. Janelle  
Signature

Dawn M. Janelle

Typed or Printed Name of Person Signing Certificate

Mail Stop: Missing Parts  
Commissioner for Patents  
P.O Box 1450  
Alexandria, VA 22313-1450

REPLY TO THE NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES

Sir:

This paper is timely filed in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on July 5, 2006 (referred to hereinafter as the "Notification"). The Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account No. 50-0590.

In the Notification, the Office alleges that the instant application fails to comply with the requirements of 37 CFR 1.821-1.825.

According to 37 CFR 1.821(a)(1)(2) "those amino acid sequences containing D-amino acids are not intended to be embraced by this definition." Applicants submit that each sequence contemplated for use in the practice of the instant invention contains at least one D-amino acid. In accordance with 37 CFR 1.821(a)(1)(2), Applicant submits that all sequences of the invention are exempt from the definition of those amino acid sequences requiring recitation in a sequence listing

Reconsideration of the instant Notification and its requirements is respectfully requested. Prompt and favorable action is solicited.

Please apply any charges or credits to Deposit Account No. 50-0590 referencing attorney docket number 131P/PCT2/US.

Respectfully submitted,

Date:

7/12/06

Pamela C Ball

Pamela C. Ball  
Agent for Applicant(s)  
Reg. No. 53,963

Biomeasure, Incorporated  
27 Maple Street  
Milford, MA 01757-3650  
(508) 478-0144 Telephone  
(508) 478-2530 Facsimile